What is the primary purpose of USP General Chapter ?

USP establishes standards for compounding sterile preparations (CSPs) to prevent harm to patients, including microbial contamination, pyrogens, and errors in compounding.

How does USP General Chapter relate to sterile compounding?

USP provides standards for handling hazardous drugs to promote patient safety, worker safety, and environmental protection. It applies to all healthcare personnel who compound or administer hazardous drugs, regardless of whether they are sterile or non-sterile.

What are the different risk levels for sterile compounding under USP ?

USP categorizes CSPs into Low-Risk, Medium-Risk, and High-Risk levels, primarily based on the complexity of compounding, the number of sterile products combined, and the exposure to air or critical sites.

What ISO classifications are typically required for sterile compounding environments?

A Primary Engineering Control (PEC) like a laminar airflow workbench (LAFW) or compounding aseptic isolator (CAI) must meet ISO Class 5 conditions. The buffer area (where the PEC is located) must be at least ISO Class 7, and the ante-room (if separate) must be at least ISO Class 8 (or ISO Class 7 if it opens directly into a PEC located in a negative pressure room).

What is a Beyond-Use Date (BUD) and how is it determined for CSPs?

A Beyond-Use Date (BUD) is the date and time after which a compounded sterile preparation (CSP) should not be stored or used. It is determined by the lowest of the drug's expiration date, stability data, and the USP risk level criteria for microbial sterility, considering storage conditions.

What is the difference between a 503A and a 503B compounding pharmacy?

A 503A compounding pharmacy typically compounds for specific patient prescriptions under state boards of pharmacy oversight. A 503B outsourcing facility can compound sterile preparations in bulk without patient-specific prescriptions, subject to FDA's current Good Manufacturing Practices (cGMP) and more rigorous oversight.

Mastering Sterile Compounding Regulations for the CPIP Certified Pharmaceutical Industry Professional Exam

As an aspiring CPIP Certified Pharmaceutical Industry Professional, understanding the intricate landscape of sterile compounding regulations is not merely an academic exercise—it's a fundamental requirement for ensuring patient safety and regulatory compliance within the pharmaceutical industry. The CPIP exam, designed to validate expertise in critical areas of pharmaceutical development, manufacturing, and quality, places significant emphasis on regulatory adherence, particularly in high-risk areas like sterile compounding. This mini-article, authored by the experts at PharmacyCert.com as of April 2026, will guide you through the essential concepts, their relevance to the CPIP exam, and effective study strategies.

Introduction to Sterile Compounding Regulations

Sterile compounding involves the preparation of customized sterile medications for individual patients. This process is inherently complex and carries significant risks if not performed under stringent controls. Contamination, errors in formulation, or incorrect labeling can lead to severe patient harm, including infections, adverse drug reactions, or even death. Consequently, sterile compounding is one of the most heavily regulated aspects of pharmacy practice and pharmaceutical manufacturing.

For the CPIP Certified Pharmaceutical Industry Professional, a deep understanding of these regulations is paramount. The exam assesses your ability to navigate the regulatory frameworks governing drug product quality, safety, and efficacy. Sterile compounding regulations, primarily driven by the United States Pharmacopeia (USP) General Chapters and reinforced by the Food and Drug Administration (FDA), form a critical component of this knowledge base. Your role, whether in quality assurance, regulatory affairs, manufacturing, or product development, will invariably intersect with these standards, making them a cornerstone of your professional competency.

The CPIP exam expects you to not only recall facts but also to apply regulatory principles to real-world scenarios, identify potential compliance gaps, and propose solutions that uphold the highest standards of pharmaceutical care. For a comprehensive overview of the CPIP exam, consult our Complete CPIP Certified Pharmaceutical Industry Professional Guide.

Key Concepts in Sterile Compounding Regulations

The regulatory framework for sterile compounding in the United States is primarily defined by two critical USP General Chapters: USP General Chapter <797> "Pharmaceutical Compounding - Sterile Preparations" and USP General Chapter <800> "Hazardous Drugs - Handling in Healthcare Settings." Additionally, FDA oversight plays a crucial role, particularly for larger compounding operations.

USP General Chapter <797>: Pharmaceutical Compounding - Sterile Preparations

USP <797> sets the standards for all persons who prepare compounded sterile preparations (CSPs) and specifies the conditions and practices required to prevent contamination and ensure sterility. Key areas include:

Personnel Training and Competency: All personnel involved in sterile compounding must be adequately trained, demonstrate competency (e.g., media fill tests, gloved fingertip/thumb sampling), and undergo regular re-evaluation. This includes aseptic technique, garbing, and environmental monitoring procedures.
Environmental Controls: This is a cornerstone of <797>.
- Primary Engineering Controls (PECs): Devices that provide an ISO Class 5 environment (e.g., Laminar Airflow Workbenches (LAFWs), Compounding Aseptic Isolators (CAIs), Biological Safety Cabinets (BSCs)).
- Secondary Engineering Controls (SECs): The room where the PEC is located, often referred to as the "buffer area," which must maintain at least ISO Class 7 conditions.
- Ante-Room: A transition area between the unclassified space and the buffer area, typically ISO Class 8, or ISO Class 7 if it opens directly into a negative pressure buffer area.
- Airflow Requirements: Positive pressure in the buffer area relative to the ante-room (for non-hazardous CSPs) to protect the product from external contamination.
Risk Levels and Beyond-Use Dates (BUDs): <797> categorizes CSPs into risk levels based on the potential for microbial contamination:
- Low-Risk: Compounding involves combining no more than three commercially manufactured sterile products and no more than two entries into any one sterile container. BUDs are relatively short (e.g., 48 hours room temperature, 14 days refrigerated).
- Medium-Risk: Multiple individual or small doses of sterile products are combined or pooled to prepare a CSP that will be administered to multiple patients or to one patient on multiple occasions. BUDs are longer than low-risk (e.g., 30 hours room temperature, 9 days refrigerated).
- High-Risk: Non-sterile ingredients are used, or sterile ingredients are exposed to air quality worse than ISO Class 5 for more than one hour, or non-sterile water-containing preparations are stored for more than 6 hours before sterilization. Requires terminal sterilization or sterility testing. BUDs are shortest without sterility testing (e.g., 24 hours room temperature, 3 days refrigerated).
- Immediate-Use: For emergency situations, prepared in an uncontrolled environment, must be administered within 1 hour.
BUDs are crucial and depend on the risk level, storage conditions, and verified stability data.
Quality Assurance and Quality Control (QA/QC): Includes environmental monitoring (viable and non-viable particle counts), surface sampling, equipment calibration, and documentation.

USP General Chapter <800>: Hazardous Drugs - Handling in Healthcare Settings

While <797> focuses on sterility, <800> addresses the safe handling of hazardous drugs (HDs) to protect healthcare personnel, patients, and the environment. It applies to all healthcare settings where HDs are handled, from receipt to administration. Key aspects include:

Containment Strategy: Requires specific engineering controls for HDs.
- Containment Primary Engineering Control (C-PEC): A ventilated device designed to minimize exposure to HDs (e.g., Class II or III Biological Safety Cabinet, Compounding Aseptic Containment Isolator (CACI)). Must be externally vented.
- Containment Secondary Engineering Control (C-SEC): The room where the C-PEC is located. Must be externally vented, have negative pressure relative to adjacent areas, and have at least 12 air changes per hour (ACPH).
Personnel Protection: Mandates the use of appropriate Personal Protective Equipment (PPE) such as chemotherapy gloves, gowns, and respiratory protection, depending on the activity and drug type.
Deactivation, Decontamination, Cleaning, and Disinfection: Specific procedures are required for surfaces potentially contaminated with HDs.
Receiving, Storing, and Dispensing: Requirements for handling HDs throughout their lifecycle in the facility.

FDA Oversight and cGMPs

Beyond USP, the FDA plays a significant role, particularly with larger-scale compounding operations. The Drug Quality and Security Act (DQSA) of 2013 created two categories of compounding pharmacies:

503A Compounding Pharmacies: Compound pursuant to a patient-specific prescription, primarily regulated by state boards of pharmacy, and generally exempt from FDA's new drug approval process, cGMP requirements, and drug labeling requirements. They must comply with USP standards.
503B Outsourcing Facilities: Register with the FDA and can compound sterile preparations in bulk without patient-specific prescriptions. They are subject to FDA's current Good Manufacturing Practices (cGMP) requirements, facility inspections, and other FDA oversight, similar to traditional pharmaceutical manufacturers. This distinction is critical for CPIP candidates involved in manufacturing or quality roles.

How It Appears on the Exam

The CPIP exam will test your knowledge of sterile compounding regulations through various question styles:

Direct Recall: Questions asking for specific ISO classifications, BUDs for certain risk levels, or the purpose of a particular USP chapter.
- Example: "According to USP <797>, what is the maximum Beyond-Use Date for a refrigerated Low-Risk Compounded Sterile Preparation?"
Scenario-Based Questions: You might be presented with a description of a compounding facility or a specific compounding process and asked to identify non-compliance or recommend corrective actions.
- Example: "A pharmacist is preparing a sterile ophthalmic solution using non-sterile active pharmaceutical ingredients in an ISO Class 7 buffer area with a Class II Biological Safety Cabinet. The preparation will undergo terminal sterilization. What is the USP <797> risk level for this CSP?"
Comparative Analysis: Questions that require you to differentiate between <797> and <800> requirements or between 503A and 503B facilities.
- Example: "Which of the following is a primary distinction in regulatory oversight between a 503A compounding pharmacy and a 503B outsourcing facility?"
Application of Principles: Questions that assess your understanding of why certain regulations exist or how they contribute to patient safety.
- Example: "What is the primary rationale for requiring positive pressure in a non-hazardous sterile compounding buffer area?"

Study Tips for Mastering Sterile Compounding Regulations

Effective preparation for this section of the CPIP exam requires a structured approach:

Deep Dive into USP Chapters: Read and understand USP <797> and <800> thoroughly. Pay close attention to definitions, environmental control requirements (ISO classes, air changes, pressure differentials), personnel qualification, and BUD tables. While the full text is extensive, focus on the sections most relevant to daily operations and compliance.
Create Comparison Charts: Develop tables comparing <797> and <800> requirements, especially regarding engineering controls (PECs, SECs), airflow, and personnel garbing/PPE. Similarly, create a chart differentiating 503A vs. 503B facilities.
Memorize Key Numbers and Definitions: Crucial elements like ISO Class definitions (e.g., ISO 5 = 3,520 particles/m³ ≥ 0.5 µm), BUDs for different risk levels and storage conditions, and air changes per hour (ACPH) are frequently tested.
Practice Scenario-Based Questions: Work through as many practice problems as possible. This will help you apply your knowledge and identify areas where your understanding is weak. You can find excellent CPIP Certified Pharmaceutical Industry Professional practice questions on our site, including free practice questions.
Focus on the "Why": Don't just memorize what the regulations are, understand why they are in place. This will help you answer application-based questions more effectively and demonstrate E-E-A-T. For example, why is negative pressure required for hazardous drug compounding? To protect the compounder and the environment from drug exposure.
Stay Updated: Regulatory guidance, especially from USP, can evolve. Be aware of any recent revisions or impending changes to the General Chapters. As of April 2026, the current versions of these chapters are well-established, but it's always good practice to check for updates.

Common Mistakes to Watch Out For

Candidates often stumble on these points:

Confusing USP <797> and <800> Requirements: While related, they have distinct focuses. <797> is about sterility; <800> is about containment for hazardous drugs. For example, a C-PEC for hazardous compounding under <800> must be externally vented, whereas a PEC for non-hazardous sterile compounding under <797> does not necessarily need external venting.
Incorrect BUD Calculation/Application: Misinterpreting risk levels or storage conditions when determining a BUD is a common error. Always consider the most stringent limitation.
Mixing Up ISO Classifications and Pressure Differentials: Forgetting which areas require positive vs. negative pressure, or the specific ISO classes for PECs, buffer areas, and ante-rooms.
Overlooking Personnel Competency: Many candidates focus heavily on facility requirements but forget the equally critical aspect of ongoing personnel training and competency assessment.
Ignoring FDA's Role: Assuming all compounding is solely under state board oversight. Remember the distinction and implications of 503B outsourcing facilities.

Quick Review / Summary

Mastering sterile compounding regulations is indispensable for the CPIP Certified Pharmaceutical Industry Professional exam. Here’s a brief recap of the essentials:

USP <797> governs the compounding of sterile preparations, focusing on preventing contamination through strict environmental controls (ISO Class 5 PEC, ISO Class 7 buffer, ISO Class 8 ante-room), personnel competency, and risk-based BUD assignments.
USP <800> addresses the safe handling of hazardous drugs, mandating containment strategies (C-PEC, C-SEC with negative pressure and external venting) and comprehensive personnel protection.
FDA Oversight differentiates between 503A (patient-specific, state-regulated) and 503B (bulk compounding, FDA cGMP-regulated) compounding facilities.
Exam Questions will test both recall and application, often through scenarios requiring you to identify compliance issues or apply specific regulatory standards.
Study Smart by creating comparison charts, memorizing key numbers, practicing scenarios, and understanding the rationale behind each regulation.
Avoid Common Mistakes such as confusing <797> and <800>, miscalculating BUDs, or overlooking the FDA's role.

By diligently studying these regulations, you will not only be well-prepared for the CPIP exam but also contribute to the highest standards of safety and quality in pharmaceutical practice.